Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

17.69
-0.0700-0.39%
Post-market: 17.860.1700+0.96%18:15 EDT
Volume:2.13M
Turnover:37.65M
Market Cap:2.22B
PE:-9.85
High:18.09
Open:17.85
Low:17.46
Close:17.76
Loading ...

Apellis Pharmaceuticals Q1 Basic EPS USD -0.74

THOMSON REUTERS
·
07 May

Mizuho Securities Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
06 May

Apellis Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
05 May

High Growth Tech Stocks In The US For May 2025

Simply Wall St.
·
02 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
01 May

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Zacks
·
30 Apr

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

GlobeNewswire
·
30 Apr

Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now?

Insider Monkey
·
30 Apr

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks
·
29 Apr

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Apellis Pharmaceuticals (APLS) and Eton Pharmaceuticals (ETON)

TIPRANKS
·
28 Apr

Apellis Pharmaceuticals Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
22 Apr

BRIEF-Apellis Announces Craig Wheeler To Join The Board Of Directors

Reuters
·
21 Apr

RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating

MT Newswires Live
·
21 Apr

Apellis Announces Craig Wheeler to Join the Board of Directors

THOMSON REUTERS
·
21 Apr

Press Release: Apellis Announces Craig Wheeler to Join the Board of Directors

Dow Jones
·
21 Apr

Apellis Pharmaceuticals Inc : RBC Cuts Target Price to $21 From $24

THOMSON REUTERS
·
21 Apr

BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating

MT Newswires Live
·
17 Apr

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

Zacks
·
15 Apr

RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating

MT Newswires Live
·
03 Apr

Apellis Pharmaceuticals Is Maintained at Sector Perform by Scotiabank

Dow Jones
·
03 Apr